AZURA OPHTHALMICS
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
AZURA OPHTHALMICS
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2014-01-01
Address:
Tel Aviv, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.azuraophthalmics.com
Total Employee:
11+
Status:
Active
Total Funding:
36 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon WordPress WP Rocket Plausible Analytics
Similar Organizations
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
Brandon BioCatalyst
Brandon BioCatalyst investment in Grant - Azura Ophthalmics
Ganot Capital
Ganot Capital investment in Series C - Azura Ophthalmics
Brandon Capital
Brandon Capital investment in Series C - Azura Ophthalmics
TPG Biotech
TPG Biotech investment in Series C - Azura Ophthalmics
OrbiMed
OrbiMed investment in Series C - Azura Ophthalmics
Ganot Capital
Ganot Capital investment in Series B - Azura Ophthalmics
OrbiMed
OrbiMed investment in Series B - Azura Ophthalmics
Brandon Capital
Brandon Capital investment in Series B - Azura Ophthalmics
TPG Biotech
TPG Biotech investment in Series B - Azura Ophthalmics
Official Site Inspections
http://www.azuraophthalmics.com Semrush global rank: 12.8 M Semrush visits lastest month: 79
- Host name: 159.89.210.140
- IP address: 159.89.210.140
- Location: Singapore
- Latitude: 1.314
- Longitude: 103.6839
- Timezone: Asia/Singapore
- Postal: 62
More informations about "Azura Ophthalmics"
About Us โ Azura Ophthalmics
Dr. Nijm advises leading medical device and pharmaceutical companies on new clinical innovations and strategic initiatives. She serves on the board of directors for the Cornea โฆSee details»
Azura Ophthalmics
Weโve set our sights on harnessing the unique properties of keratolytics to revolutionize the treatment of ophthalmic conditionsSee details»
Azura Ophthalmics - Crunchbase Company Profile & Funding
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED.See details»
Azura Ophthalmics Limited - LinkedIn
Azura Ophthalmics Limited Pharmaceutical Manufacturing Tel Aviv, Tel Aviv 1,466 followers Delivering First-in-Class Ophthalmic Keratolytics.See details»
Azura Ophthalmics - Org Chart, Teams, Culture & Jobs - The Org
Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the United States. The company is developing an innovative โฆSee details»
Azura Ophthalmics Limited Overview | SignalHire Company Profile
Organization Website: azuraophthalmics.com : Social Links: Phone Number +972 3 647 5312: Azura Ophthalmics Li... industries Pharma, Pharmaceuticals, Biotechnology: Headquarters โฆSee details»
Azura Ophthalmics - 2025 Company Profile - Tracxn
Mar 8, 2025 Azura Ophthalmics is developing therapies for meibomian gland dysfunction (MGD), an underlying cause of dry eye disease. It is working on a portfolio of compounds in โฆSee details»
Azura Ophthalmics - Portfolio Company Profile, Executives and โฆ
See Azura Ophthalmics's complete profile, including its private equity owner and the number of its executive contacts in our database. Azura Ophthalmics is a clinical-stage biotechnology โฆSee details»
Azura Ophthalmics - Overview, News & Similar companies
Dec 18, 2023 Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort TEL AVIV, Israel & MELBOURNE, โฆSee details»
Azura Ophthalmics - VentureRadar
"Azura Ophthalmics is taking a unique pharmaceutical approach to ocular surface disease: we are developing the first ophthalmic keratolytics for the treatment of lid margin diseases such as โฆSee details»
Azura Ophthalmics - Craft
Azura Ophthalmics has 5 employees at their 1 location and $36 m in total funding,. See insights on Azura Ophthalmics including office locations, competitors, revenue, financials, executives, โฆSee details»
Azura Ophthalmics - Brandon Capital
San Francisco. Brandon Capital LLC. 1 Letterman Ave, Suite C3-330. San Francisco, CA 94129. Phone +61 3 9657 0700. Email: [email protected]See details»
Azura Ophthalmics - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Azura Ophthalmics. Use the PitchBook Platform to explore the full profile.See details»
Azura Ophthalmics Pty Ltd. (Azura Ophthalmics Pty Ltd.) - ่ฏ็ฉ็ฎก โฆ
TEL AVIV, Israel--(BUSINESS WIRE)-- Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic โฆSee details»
Azura Ophthalmics Receives $16 Million in Series B Funding to โฆ
Oct 10, 2017 โ Charles Bosworth from Allergan named as Chief Medical Officer to drive clinical strategy โ TEL AVIV, IsraelโAzura Ophthalmics Ltd. (Azura), a clinical-stage biotechnology โฆSee details»
Azura Ophthalmics - VentureRadar
Website: https://azuraophthalmics.com/ Azura Ophthalmics is taking a unique pharmaceutical approach to ocular surface disease: we are developing the first ophthalmic ...See details»
News - Brandon Capital
Sep 7, 2021 San Francisco. Brandon Capital LLC. 1 Letterman Ave, Suite C3-330. San Francisco, CA 94129. Phone +61 3 9657 0700. Email: [email protected]See details»
Patients โ Azura Ophthalmics
Azura Ophthalmics is committed to providing safe and effective therapies to patients. The indications being studied for our therapies do not qualify for Expanded Access (also known as โฆSee details»
Azura Ophthalmics Raises US$20 Million for Registration Studies โฆ
Oct 22, 2020 For more information visit: www.azuraophthalmics.com and follow Azura on LinkedIn. 1 Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the beaver dam โฆSee details»
News and Events โ Azura Ophthalmics
Sep 18, 2022 Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at American Society of Cataract and Refractive Surgery and Association for โฆSee details»